In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens
To determine the causative pathogens of otomycosis, and to evaluate the in vitro activity of antifungal agents against these pathogens. A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. The in vitro activity of fluconazole, itraconazole and voriconazole against otomyc...
Gespeichert in:
| Veröffentlicht in: | Journal of laryngology and otology 2009-09, Vol.123 (9), p.978-981 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 981 |
|---|---|
| container_issue | 9 |
| container_start_page | 978 |
| container_title | Journal of laryngology and otology |
| container_volume | 123 |
| creator | Yenişehirli, G Bulut, Y Güven, M Günday, E |
| description | To determine the causative pathogens of otomycosis, and to evaluate the in vitro activity of antifungal agents against these pathogens.
A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. The in vitro activity of fluconazole, itraconazole and voriconazole against otomycotic pathogens was tested using the E-test method.
The most common pathogen was Aspergillus fumigatus (40.6 per cent), followed by A niger (35.4 per cent), A flavus (12.5 per cent) and Candida albicans (11.5 per cent). All Aspergillus species were found to be resistant to fluconazole (minimum inhibitory concentration > or =256 microg/ml). The mean minimum inhibitory concentrations of voriconazole for A fumigatus, A niger, A flavus and C albicans were significantly lower than those of itraconazole for the same pathogens.
This study found that the most common otomycotic fungal pathogen was A fumigatus, and that voriconazole had more potent in vitro activity than itraconazole against all Aspergillus species as well as against C albicans. |
| doi_str_mv | 10.1017/S0022215109005489 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733967823</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0022215109005489</cupid><sourcerecordid>20806156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-c1a1696ff170786f2f2d08e6d33f91483aafbc662b8fd83b6964676658a8d9753</originalsourceid><addsrcrecordid>eNp9kV9rFDEUxYModlv9AL5IEKwvjt4kkz_zWIpuCwWR1ueQySRr6sxkTWaK9dObZccuKPqU5J7fudybg9ALAu8IEPn-GoBSSjiBBoDXqnmEVkTWquK1gMdotZOrnX6EjnO-BSgmoE_REWlqXhNGV8hdjvguTCliY6dQbsFlHD32_WzjaH7G3r3FRTe_X9iMHb6LKRwKGxPGPOE4xeHexilY7OdxY3q8NdPXuHFjfoaeeNNn93w5T9CXjx9uzi-qq0_ry_Ozq8rWEqbKEkNEI7wvY0olPPW0A-VEx5hvSK2YMb61QtBW-U6xtrC1kEJwZVTXSM5O0Jt9322K32eXJz2EbF3fm9HFOWvJWCOkoqyQp_8lKSgQhIsCvvoDvI1zGssWmpavJlQBFIjsIZtizsl5vU1hMOleE9C7qPRfURXPy6Xx3A6uOziWbArwegFMtqb3yYw25AeOEkWhrF-4as-FPLkfD7pJ33RRJddi_Vmv-YWs-Q3o68KzZVgztCl0G3dY6d_j_gKBe7lH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274812800</pqid></control><display><type>article</type><title>In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens</title><source>MEDLINE</source><source>Cambridge University Press Journals Complete</source><creator>Yenişehirli, G ; Bulut, Y ; Güven, M ; Günday, E</creator><creatorcontrib>Yenişehirli, G ; Bulut, Y ; Güven, M ; Günday, E</creatorcontrib><description>To determine the causative pathogens of otomycosis, and to evaluate the in vitro activity of antifungal agents against these pathogens.
A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. The in vitro activity of fluconazole, itraconazole and voriconazole against otomycotic pathogens was tested using the E-test method.
The most common pathogen was Aspergillus fumigatus (40.6 per cent), followed by A niger (35.4 per cent), A flavus (12.5 per cent) and Candida albicans (11.5 per cent). All Aspergillus species were found to be resistant to fluconazole (minimum inhibitory concentration > or =256 microg/ml). The mean minimum inhibitory concentrations of voriconazole for A fumigatus, A niger, A flavus and C albicans were significantly lower than those of itraconazole for the same pathogens.
This study found that the most common otomycotic fungal pathogen was A fumigatus, and that voriconazole had more potent in vitro activity than itraconazole against all Aspergillus species as well as against C albicans.</description><identifier>ISSN: 0022-2151</identifier><identifier>EISSN: 1748-5460</identifier><identifier>DOI: 10.1017/S0022215109005489</identifier><identifier>PMID: 19454132</identifier><identifier>CODEN: JLOTAX</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antifungal Agents ; Antifungal Agents - pharmacology ; Aspergillus - drug effects ; Aspergillus flavus ; Aspergillus fumigatus ; Biological and medical sciences ; Candida albicans ; Candida albicans - drug effects ; Candida albicans - isolation & purification ; Candidiasis - drug therapy ; Colony Count, Microbial ; Ear Diseases - microbiology ; Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology ; Fluconazole - pharmacology ; Fungus Diseases ; Humans ; Itraconazole - pharmacology ; Laboratories ; Medical sciences ; Non tumoral diseases ; Otitis Externa ; Otolaryngology ; Otorhinolaryngology. Stomatology ; Pathogens ; Pharmacology. Drug treatments ; Pyrimidines - pharmacology ; Statistical analysis ; Student's t-test ; Treatment Outcome ; Triazoles - pharmacology ; Voriconazole</subject><ispartof>Journal of laryngology and otology, 2009-09, Vol.123 (9), p.978-981</ispartof><rights>Copyright © JLO (1984) Limited 2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-c1a1696ff170786f2f2d08e6d33f91483aafbc662b8fd83b6964676658a8d9753</citedby><cites>FETCH-LOGICAL-c470t-c1a1696ff170786f2f2d08e6d33f91483aafbc662b8fd83b6964676658a8d9753</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0022215109005489/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,776,780,27901,27902,55603</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21820467$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19454132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yenişehirli, G</creatorcontrib><creatorcontrib>Bulut, Y</creatorcontrib><creatorcontrib>Güven, M</creatorcontrib><creatorcontrib>Günday, E</creatorcontrib><title>In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens</title><title>Journal of laryngology and otology</title><addtitle>J. Laryngol. Otol</addtitle><description>To determine the causative pathogens of otomycosis, and to evaluate the in vitro activity of antifungal agents against these pathogens.
A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. The in vitro activity of fluconazole, itraconazole and voriconazole against otomycotic pathogens was tested using the E-test method.
The most common pathogen was Aspergillus fumigatus (40.6 per cent), followed by A niger (35.4 per cent), A flavus (12.5 per cent) and Candida albicans (11.5 per cent). All Aspergillus species were found to be resistant to fluconazole (minimum inhibitory concentration > or =256 microg/ml). The mean minimum inhibitory concentrations of voriconazole for A fumigatus, A niger, A flavus and C albicans were significantly lower than those of itraconazole for the same pathogens.
This study found that the most common otomycotic fungal pathogen was A fumigatus, and that voriconazole had more potent in vitro activity than itraconazole against all Aspergillus species as well as against C albicans.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antifungal Agents</subject><subject>Antifungal Agents - pharmacology</subject><subject>Aspergillus - drug effects</subject><subject>Aspergillus flavus</subject><subject>Aspergillus fumigatus</subject><subject>Biological and medical sciences</subject><subject>Candida albicans</subject><subject>Candida albicans - drug effects</subject><subject>Candida albicans - isolation & purification</subject><subject>Candidiasis - drug therapy</subject><subject>Colony Count, Microbial</subject><subject>Ear Diseases - microbiology</subject><subject>Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology</subject><subject>Fluconazole - pharmacology</subject><subject>Fungus Diseases</subject><subject>Humans</subject><subject>Itraconazole - pharmacology</subject><subject>Laboratories</subject><subject>Medical sciences</subject><subject>Non tumoral diseases</subject><subject>Otitis Externa</subject><subject>Otolaryngology</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>Pathogens</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrimidines - pharmacology</subject><subject>Statistical analysis</subject><subject>Student's t-test</subject><subject>Treatment Outcome</subject><subject>Triazoles - pharmacology</subject><subject>Voriconazole</subject><issn>0022-2151</issn><issn>1748-5460</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kV9rFDEUxYModlv9AL5IEKwvjt4kkz_zWIpuCwWR1ueQySRr6sxkTWaK9dObZccuKPqU5J7fudybg9ALAu8IEPn-GoBSSjiBBoDXqnmEVkTWquK1gMdotZOrnX6EjnO-BSgmoE_REWlqXhNGV8hdjvguTCliY6dQbsFlHD32_WzjaH7G3r3FRTe_X9iMHb6LKRwKGxPGPOE4xeHexilY7OdxY3q8NdPXuHFjfoaeeNNn93w5T9CXjx9uzi-qq0_ry_Ozq8rWEqbKEkNEI7wvY0olPPW0A-VEx5hvSK2YMb61QtBW-U6xtrC1kEJwZVTXSM5O0Jt9322K32eXJz2EbF3fm9HFOWvJWCOkoqyQp_8lKSgQhIsCvvoDvI1zGssWmpavJlQBFIjsIZtizsl5vU1hMOleE9C7qPRfURXPy6Xx3A6uOziWbArwegFMtqb3yYw25AeOEkWhrF-4as-FPLkfD7pJ33RRJddi_Vmv-YWs-Q3o68KzZVgztCl0G3dY6d_j_gKBe7lH</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Yenişehirli, G</creator><creator>Bulut, Y</creator><creator>Güven, M</creator><creator>Günday, E</creator><general>Cambridge University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20090901</creationdate><title>In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens</title><author>Yenişehirli, G ; Bulut, Y ; Güven, M ; Günday, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-c1a1696ff170786f2f2d08e6d33f91483aafbc662b8fd83b6964676658a8d9753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antifungal Agents</topic><topic>Antifungal Agents - pharmacology</topic><topic>Aspergillus - drug effects</topic><topic>Aspergillus flavus</topic><topic>Aspergillus fumigatus</topic><topic>Biological and medical sciences</topic><topic>Candida albicans</topic><topic>Candida albicans - drug effects</topic><topic>Candida albicans - isolation & purification</topic><topic>Candidiasis - drug therapy</topic><topic>Colony Count, Microbial</topic><topic>Ear Diseases - microbiology</topic><topic>Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology</topic><topic>Fluconazole - pharmacology</topic><topic>Fungus Diseases</topic><topic>Humans</topic><topic>Itraconazole - pharmacology</topic><topic>Laboratories</topic><topic>Medical sciences</topic><topic>Non tumoral diseases</topic><topic>Otitis Externa</topic><topic>Otolaryngology</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>Pathogens</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrimidines - pharmacology</topic><topic>Statistical analysis</topic><topic>Student's t-test</topic><topic>Treatment Outcome</topic><topic>Triazoles - pharmacology</topic><topic>Voriconazole</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yenişehirli, G</creatorcontrib><creatorcontrib>Bulut, Y</creatorcontrib><creatorcontrib>Güven, M</creatorcontrib><creatorcontrib>Günday, E</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of laryngology and otology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yenişehirli, G</au><au>Bulut, Y</au><au>Güven, M</au><au>Günday, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens</atitle><jtitle>Journal of laryngology and otology</jtitle><addtitle>J. Laryngol. Otol</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>123</volume><issue>9</issue><spage>978</spage><epage>981</epage><pages>978-981</pages><issn>0022-2151</issn><eissn>1748-5460</eissn><coden>JLOTAX</coden><abstract>To determine the causative pathogens of otomycosis, and to evaluate the in vitro activity of antifungal agents against these pathogens.
A total of 96 fungal isolate were taken from 92 patients suspected of otomycosis. The in vitro activity of fluconazole, itraconazole and voriconazole against otomycotic pathogens was tested using the E-test method.
The most common pathogen was Aspergillus fumigatus (40.6 per cent), followed by A niger (35.4 per cent), A flavus (12.5 per cent) and Candida albicans (11.5 per cent). All Aspergillus species were found to be resistant to fluconazole (minimum inhibitory concentration > or =256 microg/ml). The mean minimum inhibitory concentrations of voriconazole for A fumigatus, A niger, A flavus and C albicans were significantly lower than those of itraconazole for the same pathogens.
This study found that the most common otomycotic fungal pathogen was A fumigatus, and that voriconazole had more potent in vitro activity than itraconazole against all Aspergillus species as well as against C albicans.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>19454132</pmid><doi>10.1017/S0022215109005489</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2151 |
| ispartof | Journal of laryngology and otology, 2009-09, Vol.123 (9), p.978-981 |
| issn | 0022-2151 1748-5460 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733967823 |
| source | MEDLINE; Cambridge University Press Journals Complete |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antifungal Agents Antifungal Agents - pharmacology Aspergillus - drug effects Aspergillus flavus Aspergillus fumigatus Biological and medical sciences Candida albicans Candida albicans - drug effects Candida albicans - isolation & purification Candidiasis - drug therapy Colony Count, Microbial Ear Diseases - microbiology Ear, auditive nerve, cochleovestibular tract, facial nerve: diseases, semeiology Fluconazole - pharmacology Fungus Diseases Humans Itraconazole - pharmacology Laboratories Medical sciences Non tumoral diseases Otitis Externa Otolaryngology Otorhinolaryngology. Stomatology Pathogens Pharmacology. Drug treatments Pyrimidines - pharmacology Statistical analysis Student's t-test Treatment Outcome Triazoles - pharmacology Voriconazole |
| title | In vitro activities of fluconazole, itraconazole and voriconazole against otomycotic fungal pathogens |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T18%3A12%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activities%20of%20fluconazole,%20itraconazole%20and%20voriconazole%20against%20otomycotic%20fungal%20pathogens&rft.jtitle=Journal%20of%20laryngology%20and%20otology&rft.au=Yeni%C5%9Fehirli,%20G&rft.date=2009-09-01&rft.volume=123&rft.issue=9&rft.spage=978&rft.epage=981&rft.pages=978-981&rft.issn=0022-2151&rft.eissn=1748-5460&rft.coden=JLOTAX&rft_id=info:doi/10.1017/S0022215109005489&rft_dat=%3Cproquest_cross%3E20806156%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274812800&rft_id=info:pmid/19454132&rft_cupid=10_1017_S0022215109005489&rfr_iscdi=true |